GlobeNewswire: Lisata Therapeutics Contains the last 10 of 435 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:11:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850166/0/en/Lisata-Therapeutics-Announces-U-S-FDA-Rare-Pediatric-Disease-Designation-Granted-to-LSTA1-for-the-Treatment-of-Osteosarcoma.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma2024-03-21T12:00:00Z<![CDATA[Achieves critical first step toward priority review voucher Achieves critical first step toward priority review voucher]]>https://www.globenewswire.com/news-release/2024/02/29/2838385/0/en/Lisata-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update2024-02-29T21:05:00Z<![CDATA[Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024]]>https://www.globenewswire.com/news-release/2024/02/22/2833625/0/en/Lisata-Therapeutics-to-Host-Year-End-2023-Conference-Call-on-Thursday-February-29-2024-at-4-30-p-m-Eastern-Time.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time2024-02-22T13:00:00Z<![CDATA[BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for twelve months ended December 31, 2023, on Thursday, February 29, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.]]>https://www.globenewswire.com/news-release/2024/02/20/2831757/0/en/Lisata-Therapeutics-to-Present-at-BIO-CEO-Investor-Conference.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics to Present at BIO CEO & Investor Conference2024-02-20T13:00:00Z<![CDATA[BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City.]]>https://www.globenewswire.com/news-release/2024/01/17/2810664/0/en/Lisata-Therapeutics-Announces-First-Patient-Treated-in-the-Phase-2a-Trial-of-LSTA1-in-Patients-with-Glioblastoma-Multiforme.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme2024-01-17T13:00:00Z<![CDATA[BASKING RIDGE, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (“GBM”). The trial is an investigator-initiated study by Lenne-Triin Kõrgvee, MD, PhD, principal investigator of the study. The first patient was enrolled at Tartu University Hospital in Tartu, Estonia.]]>https://www.globenewswire.com/news-release/2024/01/04/2803930/0/en/Lisata-Therapeutics-Announces-Publication-of-Case-Report-on-a-Complete-Response-in-a-Metastatic-Gastroesophageal-Adenocarcinoma-Patient-Treated-with-LSTA1-in-Combination-with-Stand.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy2024-01-04T13:00:00Z<![CDATA[LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma]]>https://www.globenewswire.com/news-release/2023/12/12/2794698/0/en/Lisata-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-2b-ASCEND-Trial-of-LSTA1-in-Metastatic-Pancreatic-Ductal-Adenocarcinoma.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma2023-12-12T13:00:00Z<![CDATA[Enrollment completed approximately six months earlier than originally projected]]>https://www.globenewswire.com/news-release/2023/11/28/2787351/0/en/Lisata-Therapeutics-to-Present-at-NobleCon19-Investor-Conference.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics to Present at NobleCon19 Investor Conference2023-11-28T21:05:00Z<![CDATA[BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.]]>https://www.globenewswire.com/news-release/2023/11/09/2777838/0/en/Lisata-Therapeutics-Announces-Participation-in-Upcoming-Conferences-in-November.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Announces Participation in Upcoming Conferences in November2023-11-09T21:05:00Z<![CDATA[BASKING RIDGE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at the following conferences in November:]]>https://www.globenewswire.com/news-release/2023/11/02/2772808/0/en/Lisata-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=14410Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-02T20:05:00Z<![CDATA[Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued rapid enrollment in ASCEND]]>